Nanjing Hanxin Pharmaceutical Technology — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

An R&D-focused biopharma developing novel small molecule drugs for oncology and immunology.

OncologyImmunology

Employs structure-based drug design and screening platforms to discover and optimize novel small molecule therapeutics.

Potential to develop best-in-class or first-in-class small molecule drugs for validated targets in large markets.

High clinical attrition risk and intense competition requiring clear differentiation in efficacy or safety.

Competes in the highly saturated small molecule oncology/immunology space against global pharma and numerous biotechs.